Charles Schwab
TCRX icon

Charles Schwab’s TScan Therapeutics TCRX Stock Holding History

Charles Schwab’s Portfolio TCRX Stock Details TCRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q3 		– Sell
-22,171
Closed -$32.1K – 3539
2025
Q2 		$32.1K Sell
22,171
-90,770
-80% -$131K ﹤0.01% 3476
2025
Q1 		$156K Hold
112,941
– – ﹤0.01% 3286
2024
Q4 		$343K Hold
112,941
– – ﹤0.01% 3246
2024
Q3 		$562K Hold
112,941
– – ﹤0.01% 3124
2024
Q2 		$661K Buy
112,941
+90,837
+411% +$715K ﹤0.01% 3083
2024
Q1 		$176K Hold
22,104
– – ﹤0.01% 3253
2023
Q4 		$129K Buy
+22,104
New +$101K ﹤0.01% 3329

Other funds holding TCRX

LCM
Lynx1 Capital Management San Juan, Puerto Rico $633M AUM 173.22% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
PBM
Propel Bio Management Los Angeles, California $159M AUM 60.94% 1-Year Est. Return
Aberdeen Group
Aberdeen Group Edinburgh, United Kingdom $61.9B AUM 29.81% 1-Year Est. Return
DMC
Deer Management Company Larchmont, New York $622M AUM 24.27% 1-Year Est. Return
AI
Alphabet Inc Mountain View, California $4.02B AUM 215.74% 1-Year Est. Return
SAM
Simplify Asset Management Las Vegas, Nevada $7.19B AUM 6.88% 1-Year Est. Return

Charles Schwab's TCRX Position: Q3 2025 in Review

Charles Schwab sold out of TScan Therapeutics (TCRX) in Q3 2025, closing a stake of 22,171 shares — an estimated $32.1K sold.

Charles Schwab first reported a position in TCRX in Q4 2023 and held it in 7 quarters. The position peaked at $661K in Q2 2024. 73 funds tracked by Wall St. Rank hold TCRX as of Q3 2025.

  • Charles Schwab reported no remaining TScan Therapeutics position as of Q3 2025 after selling out during the quarter.
  • Charles Schwab sold 22,171 TScan Therapeutics shares in Q3 2025, an estimated $32.1K.
  • Charles Schwab first reported a position in TScan Therapeutics in Q4 2023 and held it in 7 quarters.
  • Charles Schwab's TScan Therapeutics position peaked at $661K in Q2 2024.
  • 73 funds tracked by Wall St. Rank held TScan Therapeutics as of Q3 2025.

Based on Charles Schwab's 13F filing for Q3 2025, filed 10 Nov 2025.